Welsis (WLSS) Cash & Equivalents (2022 - 2023)
Welsis' quarterly Cash & Equivalents came in at $1368.0 in Q4 2023, down 90.43% year-on-year from $14292.0 in Q4 2022, and down 86.09% quarter-over-quarter from $9834.0 in Q3 2023.
Welsis has reported Cash & Equivalents for 2 years, with the latest figure at $1368.0 in Q4 2023.
- For the quarter ending Q4 2023, Cash & Equivalents fell 90.43% year-over-year to $1368.0; the trailing twelve-month figure through Dec 2023 stood at $1368.0 (down 90.43% YoY), and the FY2023 full-year result was $9834.0, down 47.42% from the prior year.
- Cash & Equivalents for Q4 2023 stood at $1368.0, down from $9834.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $18703.0 in Q3 2022, with the low at $963.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 1.42 Bn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 888.80 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 265.37 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 186.67 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 219.18 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 34.34 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | 490.29 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | 419.52 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 174.90 Mn |
| 10 | Welsis | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,368.00 |
| Sep 30, 2023 | 9,834.00 |
| Jun 30, 2023 | 5,202.00 |
| Mar 31, 2023 | 963.00 |
| Dec 31, 2022 | 14,292.00 |
| Sep 30, 2022 | 18,703.00 |
| Jun 30, 2022 | 1,640.00 |